Factors Associated with Efficient Harvesting and Engraftment of Auto-Transplants in Multiple Myeloma Patients

Background. The success of autologous hematopoietic stem cell transplantation (auto-HSCT) depends on the speed of transplant engraftment which in turn is affected by the count of harvested and infused hematopoietic stem cells (HSC).

Aim. To identify predictors of auto-HSCT efficacy in multiple myeloma (MM) patients under introduction of new drugs at the phase of HSC induction and mobilization.

Materials & Methods. The results of auto-transplant harvesting and engraftment were retrospectively analyzed in 75 MM patients during 112 auto-HSCTs. Auto-transplants were harvested using cyclophosphamide and vinorelbine combined with granulocyte colony-stimulating factor (G-CSF) without plerixafor. Conditioning regimen included melphalan 200 mg/m² or 140 mg/m², and combination of tiothepa with melphalan. All patients received subcutaneous injections of G-CSF in post-transplantation period. Transplant engraftment was assessed according to absolute neutrophil count of ≥ 0.5 × 10⁹/L, and thrombocyte count of ≥ 20 × 10⁹/L.

Results. It is established that the predictors of a high CD34⁺ cell count in auto-transplant are a single previous induction regimen (p = 0.0315) and administration of cyclophosphamide in mobilization regimen (р = 0.0001). Transplant engraftment period is determined by auto-HSCT serial number and amount of infused CD34⁺ cells. Hematopoiesis regeneration after the second auto-HSCT was accelerated by more frequent use of Mel140 (р = 0.001).

Conclusion. Auto-transplant quality and engraftment period in MM patients primarily depend on the efficacy of induction therapy and the intensity of HSC mobilization regimen. Therefore, induction therapy and mobilization regimen need to be tailored to an individual patient, MM prognostic variant, probability of response to standard induction regimens, and the number of planned auto-HSCTs.

• Ivan Ivanovich Kostroma Russian Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024 ; ФГБУ «Российский НИИ гематологии и трансфузиологии ФМБА», ул. 2-я Советская, д. 16, Санкт-Петербург, Российская Федерация, 191024
• A.A. Zhernyakova Russian Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024 ; ФГБУ «Российский НИИ гематологии и трансфузиологии ФМБА», ул. 2-я Советская, д. 16, Санкт-Петербург, Российская Федерация, 191024
• Zh.V. Chubukina Russian Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024 ; ФГБУ «Российский НИИ гематологии и трансфузиологии ФМБА», ул. 2-я Советская, д. 16, Санкт-Петербург, Российская Федерация, 191024
• N.Yu. Semenova Russian Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024 ; ФГБУ «Российский НИИ гематологии и трансфузиологии ФМБА», ул. 2-я Советская, д. 16, Санкт-Петербург, Российская Федерация, 191024
• I.M. Zapreeva Russian Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024 ; ФГБУ «Российский НИИ гематологии и трансфузиологии ФМБА», ул. 2-я Советская, д. 16, Санкт-Петербург, Российская Федерация, 191024
• S.A. Tiranova Russian Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024 ; ФГБУ «Российский НИИ гематологии и трансфузиологии ФМБА», ул. 2-я Советская, д. 16, Санкт-Петербург, Российская Федерация, 191024
• S.S. Bessmeltsev Russian Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024 ; ФГБУ «Российский НИИ гематологии и трансфузиологии ФМБА», ул. 2-я Советская, д. 16, Санкт-Петербург, Российская Федерация, 191024
• A.V. Chechetkin Russian Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024 ; ФГБУ «Российский НИИ гематологии и трансфузиологии ФМБА», ул. 2-я Советская, д. 16, Санкт-Петербург, Российская Федерация, 191024
• S.V. Gritsaev Russian Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024 ; ФГБУ «Российский НИИ гематологии и трансфузиологии ФМБА», ул. 2-я Советская, д. 16, Санкт-Петербург, Российская Федерация, 191024

1. Бессмельцев С.С., Абдулкадыров К.М. Множественная миелома: руководство для врачей. М.: СИМК, 2016. 512 с.
2. [Bessmeltsev SS, Abdulkadyrov KM. Mnozhestvennaya mieloma: rukovodstvo dlya vrachei. (Multiple myeloma: manual for physicians.) Moscow: SIMK Publ.; 2016. 512 p. (In Russ)]
3. Менделеева Л.П., Вотякова О.М., Покровская О.С. и др. Национальные клинические рекомендации по диагностике и лечению множественной миеломы. Гематология и трансфузиология. 2016;61(1, прил. 2):1–24. doi: 10.18821/0234-5730-2016-61-1(Прил.2).
4. [Mendeleeva LP, Votyakova OM, Pokrovskaya OS, et al. National clinical guidelines on diagnosis and treatment of multiple myeloma. Gematologiya i transfuziologiya. 2016;61(1, Suppl 2):1–24. doi: 10.18821/0234-5730-2016-61-1(Прил.2). (In Russ)
5. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875–83. doi: 10.1056/NEJMoa022340. DOI: https://doi.org/10.1056/NEJMoa022340
6. Palumbo A, Gay F, Spencer A, et al. A phase III study of ASCT vs cyclophosphamide lenalidomide dexamethasone and lenalidomide prednisone maintenance vs lenalidomide alone in newly diagnosed myeloma patients. Blood. 2013;122(21):763, abstract. DOI: https://doi.org/10.1182/blood.V122.21.763.763
7. Dhakal B, Szabo A, Chhabra S, et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis. JAMA Oncol. 2018;4(3):343–50. doi: 10.1001/jamaoncol.2017.4600. DOI: https://doi.org/10.1001/jamaoncol.2017.4600
8. Sola C, Maroto P, Salazar R, et al. Bone Marrow Transplantation: prognostic factors of peripheral blood stem cell mobilization with cyclophosphamide and filgrastim (r-metHuG-CSF): the CD34+ cell dose positively affects the time to hematopoietic recovery and supportive requirements after high-dose chemotherapy. Hematology. 1999;4(3):195–209. doi: 10.1080/10245332.1999.11746443. DOI: https://doi.org/10.1080/10245332.1999.11746443
9. Duggan PR, Guo D, Luider J, et al. Predictive factors for long term engraftment of autologous blood stem cells. Bone Marrow Transplant. 2000;26(12):1299–304. doi: 10.1038/sj.bmt.1702708. DOI: https://doi.org/10.1038/sj.bmt.1702708
10. Wallington-Beddoe CT, Gottlieb DJ, Garvin F, et al. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2009;15(11):1386–93. doi: 10.1016/j.bbmt.2009.06.018. DOI: https://doi.org/10.1016/j.bbmt.2009.06.018
11. Stiff PJ, Micallef I, Nademanee AP, et al. Transplanted CD34+ cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biol Blood Marrow Transplant. 2011;17(8):1146–53. doi: 10.1016/j.bbmt.2010.11.021. DOI: https://doi.org/10.1016/j.bbmt.2010.11.021
12. Asfour I, Afify H, Elkourashy S, et al. CXCR4 (CD184) expression on stem cell harvest and CD34+ cells post-transplant. Hematol Oncol Stem Cell Ther. 2017;10(2):63–9. doi: 10.1016/j.hemonc.2017.01.002. DOI: https://doi.org/10.1016/j.hemonc.2017.01.002
13. Кострома И.И., Жернякова А.А., Чубукина Ж.В. и др. Заготовка гемопоэтических стволовых клеток у больных множественной миеломой: влияние предшествующей аутоТГСК терапии леналидомидом и режима мобилизации. Клиническая онкогематология. 2018;11(2):192–7. doi: 10.21320/2500-2139-2018-11-2-192-197. DOI: https://doi.org/10.21320/2500-2139-2018-11-2-192-197
14. [Kostroma II, Zhernyakova AA, Chubukina ZhV, et al. Hematopoietic Stem Cell Collection in Multiple Myeloma Patients: Influence of the Lenalidomide-Based Therapy and Mobilization Regimen Prior to Auto-HSCT. Clinical oncohematology. 2018;11(2);192–7. doi: 10.21320/2500-2139-2018-11-2-192-197. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2018-11-2-192-197
15. Stewart DA, Guo D, Morris D, et al. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens. Bone Marrow Transplant. 1999;23(2):111–7. doi: 10.1038/sj.bmt.1701536. DOI: https://doi.org/10.1038/sj.bmt.1701536
16. Corso A, Caberlon S, Pagnucco G, et al. Blood stem cell collections in multiple myeloma: definition of a scoring system. Bone Marrow Transplant. 2000;26(3):283–6. doi: 10.1038/sj.bmt.1702514. DOI: https://doi.org/10.1038/sj.bmt.1702514
17. Morris CL, Siegel E, Barlogie B, et al. Mobilization of CD34+ cells in elderly patients (≥70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol. 2003;120(3):413–23. doi: 10.1046/j.1365-2141.2003.04107.x. DOI: https://doi.org/10.1046/j.1365-2141.2003.04107.x
18. Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008;14(9):1045–56. doi: 10.1016/j.bbmt.2008.07.004. DOI: https://doi.org/10.1016/j.bbmt.2008.07.004
19. Lee JL, Kim SB, Lee GW, et al. Collection of peripheral blood progenitor cells: analysis of factors predicting the yields. Transfus Apher Sci. 2003;29(1):29–37. doi: 10.1016/S1473-0502(03)00097-1. DOI: https://doi.org/10.1016/S1473-0502(03)00097-1
20. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007;21(9):2035–42. doi: 10.1038/sj.leu.2404801. DOI: https://doi.org/10.1038/sj.leu.2404801
21. Mark T, Stern J, Furst JR, et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant. 2008;14(7):795–8. doi: 10.1016/j.bbmt.2008.04.008. DOI: https://doi.org/10.1016/j.bbmt.2008.04.008
22. DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720–6. doi: 10.1182/blood-2008-08-174946. DOI: https://doi.org/10.1182/blood-2008-08-174946
23. Popat U, Saliba R, Thandi R, et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009;15(6):718–23. doi: 10.1016/j.bbmt.2009.02.011. DOI: https://doi.org/10.1016/j.bbmt.2009.02.011
24. Ruiz-Delgado GJ, Lopez-Otero A, Hernandez-Arizpe A, et al. Poor hematopoietic stem cell mobilizers in multiple myeloma: a single institution experience. Medit J Hemat Infect Dis. 2010;2(2):e2010016. doi: 10.4084/MJHID.2010.016. DOI: https://doi.org/10.4084/mjhid.2010.016
25. Mohty M, Hubel K, Kroger N, et al. Autologous haematopoietic stem cell mobilization in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014;49(7):865–72. doi: 10.1038/bmt.2014.39. DOI: https://doi.org/10.1038/bmt.2014.39
26. Silvennoinen R, Anttila P, Saily M, et al. A randomized phase II study of stem cell mobilization with cyclophosphamide + G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma. Bone Marrow Transplant. 2016:51(3):372–6. doi: 10.1038/bmt.2015.236. DOI: https://doi.org/10.1038/bmt.2015.236
27. Sarmiento M, Ramirez P, Parody R, et al. Advantages of non-cryopreserved autologous hematopoietic stem cell transplantation against a cryopreserved strategy. Bone Marrow Transplant. 2018;53(8):960–6. doi: 10.1038/s41409-018-0117-5. DOI: https://doi.org/10.1038/s41409-018-0117-5
28. Кучер M.A., Моталкина М.С., Климова О.У. и др. Плериксафор у пациентов со сниженной мобилизационной способностью аутологичных гемопоэтических стволовых клеток. Клиническая онкогематология. 2016;9(2):155–61. doi: 10.21320/2500-2139-2016-9-2-155-161. DOI: https://doi.org/10.21320/2500-2139-2016-9-2-155-161
29. [Kucher MA, Motalkina MS, Klimova OU, et al. Plerixafor in Patients with Decreased Mobilizing Ability of Autologous Hematopoietic Stem Cells. Clinical oncohematology. 2016;9(2):155–61. doi: 10.21320/2500-2139-2016-9-2-155-161. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2016-9-2-155-161
30. Грицаев C.В., Кострома И.И., Чубукина Ж.В. и др. Сравнительная эффективность винорелбина и циклофосфана в режиме мобилизации для заготовки аутотрансплантата. Medline.ru. 2017;18:409–24.
31. [Gritsaev SV, Kostroma II, Chubukina ZhV, et al. Comparative efficacy of vinorelbine and cyclophosphamide in mobilization regimen for auto-transplant harvesting. Medline.ru. 2017;18:409–24. (In Russ)]
32. Грицаев С.В., Кузяева А.А., Кострома И.И. и др. Первый опыт мобилизации гемопоэтических стволовых клеток в периферическую кровь винорелбином у больных лимфопролиферативными заболеваниями. Медицина экстремальных ситуаций. 2017;62(4):30–5.
33. [Gritsaev SV, Kuzyaeva AA, Kostroma II, et al. The first attempt to use vinorelbine for mobilization of hematopoietic stem cells into the peripheral blood in patients with lymphoproliferative disoders. Meditsina ekstremal’nykh situatsii. 2017;62(4):30–5. (In Russ)]